Abstract

During HIV infection, cell-to-cell transmission results in endosomal uptake of the virus by target CD4+ T cells and potential exposure of the viral ssRNA genome to endosomal Toll-like receptors (TLRs). TLRs are instrumental in activating inflammatory responses in innate immune cells, but their function in adaptive immune cells is less well understood. Here we show that synthetic ligands of TLR8 boosted T cell receptor signaling, resulting in increased cytokine production and upregulation of surface activation markers. Adjuvant TLR8 stimulation, but not TLR7 or TLR9, further promoted T helper cell differentiation towards Th1 and Th17. In addition, we found that endosomal HIV induced cytokine secretion from CD4+ T cells in a TLR8-specific manner. TLR8 engagement also enhanced HIV-1 replication and potentiated the reversal of latency in patient-derived T cells. The adjuvant TLR8 activity in T cells can contribute to viral dissemination in the lymph node and low-grade inflammation in HIV patients. In addition, it can potentially be exploited for therapeutic targeting and vaccine development.

Manipulation of Toll-like receptors (TLRs) affects HIV-1 infection and latency reversal. Here, the authors show that HIV-1 is endocytosed and recognized by TLR8 in human primary CD4+T cells and that TLR8 stimulation induces an inflammatory response that promotes HIV-1 replication and reversal of latency.

Details

Title
Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
Author
Meås, Hany Zekaria 1 ; Haug, Markus 1   VIAFID ORCID Logo  ; Beckwith, Marianne Sandvold 2   VIAFID ORCID Logo  ; Louet Claire 2   VIAFID ORCID Logo  ; Ryan, Liv 2 ; Hu Zhenyi 3 ; Landskron Johannes 4   VIAFID ORCID Logo  ; Nordbø, Svein Arne 5   VIAFID ORCID Logo  ; Taskén Kjetil 6 ; Yin Hang 7   VIAFID ORCID Logo  ; Damås, Jan Kristian 1   VIAFID ORCID Logo  ; Flo, Trude Helen 8   VIAFID ORCID Logo 

 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Infectious Diseases, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560) 
 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) 
 Tsinghua University, School of Pharmaceutical Sciences, Tsinghua University—Peking University Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178) ; University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
 University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Medical Microbiology, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560) 
 University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) ; Oslo University Hospital, Department of Cancer Immunology, Institute of Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485) ; University of Oslo, K.G. Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
 Tsinghua University, School of Pharmaceutical Sciences, Tsinghua University—Peking University Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178) 
 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Infectious Diseases, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560) ; University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2342964239
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.